Semax (synthetic ACTH analogue)
What it is
A synthetic heptapeptide analogue of ACTH(4-10) developed in Russia and approved there for cognitive disorders and stroke recovery. Enhances BDNF expression and modulates dopaminergic and serotonergic systems. Russian clinical data shows improved memory, attention, and stroke recovery. No Western regulatory approval. Administered as a nasal spray. Limited independent replication of Russian studies.
Dose
200–600 mcg/day intranasal; approved only in Russia and Ukraine; no Western regulatory approval
Time of day & tips
Nasal spray administration only — oral ingestion destroys the peptide. Regulatory grey area in most Western countries. Russian clinical evidence is encouraging but not independently confirmed. Short half-life requires 2–3 daily doses.
Compare or learn more
Compare with another supplement →
Browse by symptom →
Open the full interactive view →